NASDAQ:CNSP

CNS Pharmaceuticals Q3 2025 Earnings Results & Report

CNS Pharmaceuticals logo
$4.26 +0.11 (+2.67%)
Closing price 03:58 PM Eastern
Extended Trading
$4.26 0.00 (-0.02%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CNS Pharmaceuticals beat analyst earnings expectations in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$5.76 versus the -$6.63 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
4:00 PM ET

CNS Pharmaceuticals EPS Results

Actual EPS
-$5.76
Consensus EPS
-$6.63
Beat/Miss
Beat by +$0.87
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 6 quarters

CNS Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

CNS Pharmaceuticals Q3 2025 Earnings FAQ

CNS Pharmaceuticals (NASDAQ:CNSP) reported earnings of -$5.76 per share for Q3 2025, beating the consensus estimate of -$6.63. The report was announced on Friday, November 14, 2025.

CNS Pharmaceuticals Earnings Headlines

Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More CNS Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CNS Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CNS Pharmaceuticals and other key companies, straight to your email.

About CNS Pharmaceuticals

CNS Pharmaceuticals (NASDAQ:CNSP) is a biopharmaceutical company focused on developing treatments for cancers of the brain and central nervous system. Its research has centered on investigational therapies intended to address the challenges of treating tumors that affect these areas.

The company’s lead candidate has been berubicin, an experimental anthracycline designed to cross the blood-brain barrier. CNS Pharmaceuticals has evaluated berubicin for glioblastoma, an aggressive form of brain cancer. The drug remains investigational and is not an approved treatment.

The company has also pursued other experimental compounds for brain and central nervous system conditions. Its work has included clinical development and research; it does not market an established portfolio of approved medicines.

View CNS Pharmaceuticals Profile